T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.835 NOK 10.74% Market Closed
Market Cap: 665.8m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

Thor Medical ASA
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Thor Medical ASA
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
T
Thor Medical ASA
OSE:TRMED
PP&E Net
kr1.9m
CAGR 3-Years
-46%
CAGR 5-Years
-40%
CAGR 10-Years
12%
Hofseth Biocare ASA
OSE:HBC
PP&E Net
kr145.6m
CAGR 3-Years
-8%
CAGR 5-Years
2%
CAGR 10-Years
5%
B
Bergenbio ASA
OSE:BGBIO
PP&E Net
kr115k
CAGR 3-Years
-57%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
PP&E Net
kr548k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
PP&E Net
kr23.3m
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
15%
N
Nykode Therapeutics ASA
OSE:NYKD
PP&E Net
$9.3m
CAGR 3-Years
243%
CAGR 5-Years
159%
CAGR 10-Years
N/A
No Stocks Found

Thor Medical ASA
Glance View

Market Cap
665.8m NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

TRMED Intrinsic Value
0.124 NOK
Overvaluation 96%
Intrinsic Value
Price
T

See Also

What is Thor Medical ASA's PP&E Net?
PP&E Net
1.9m NOK

Based on the financial report for Jun 30, 2024, Thor Medical ASA's PP&E Net amounts to 1.9m NOK.

What is Thor Medical ASA's PP&E Net growth rate?
PP&E Net CAGR 10Y
12%

Over the last year, the PP&E Net growth was 850%. The average annual PP&E Net growth rates for Thor Medical ASA have been -46% over the past three years , -40% over the past five years , and 12% over the past ten years .

Back to Top